A Look At Alnylam Pharmaceuticals (ALNY) Valuation As It Previews New Five Year Plan And Revenue Outlook

Alnylam Pharmaceuticals (ALNY) is in focus as management prepares to outline a new five year plan at the 44th Annual J.P. Morgan Healthcare Conference, along with preliminary 2025 revenue updates and a 2026 outlook.

See our latest analysis for Alnylam Pharmaceuticals.

At a share price of $422.5, recent trading has been choppy, with a 1-day share price return of 3.96% and 7-day share price return of 6.25%, set against a 90-day share price return of 7.54%. The 1-year total shareholder return of 75.64% points to momentum that has built over a longer period as investors weigh growth potential and changing perceptions of risk around Alnylam’s pipeline and upcoming five year plan.

If events at Alnylam have your attention, it could be a useful moment to see what else is happening across healthcare stocks as another source of ideas.

With shares at $422.50, a value score of 2 and an indicated 51.6% intrinsic discount, Alnylam screens as anything but cheap on headlines. Is there still a mispricing here, or is the market already baking in the next leg of growth?

Most Popular Narrative Narrative: 14.1% Undervalued

Compared with the last close of $422.50, the most followed narrative points to a higher fair value, built around Alnylam’s RNAi growth story and operating leverage.

The analysts have a consensus price target of $426.26 for Alnylam Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $583.0, and the most bearish reporting a price target of $236.0.

Read the complete narrative.

Curious what sits behind the near US$492 fair value? It reflects rapid revenue expansion, a sharp margin shift and a future earnings multiple that assumes serious staying power.

Result: Fair Value of $491.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that picture could shift quickly if AMVUTTRA pricing and reimbursement tighten, or if heavy TTR reliance meets tougher competition and puts pressure on earnings relative to current expectations.

Find out about the key risks to this Alnylam Pharmaceuticals narrative.

Another View: Multiples Point To A Full Price

Our fair value work suggests Alnylam is 51.6% undervalued, but the simple P/S check tells a different story. At 17.4x sales versus 12.1x for the US biotech group and 9.2x for peers, and above a 16.7x fair ratio, the stock already looks richly priced. Which signal do you trust more right now?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Alnylam Pharmaceuticals Narrative

If you look at these numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a personalized view in just a few minutes with Do it your way.

A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one company, you risk missing other opportunities. Use the Simply Wall St Screener to scan for ideas that truly fit your approach.

• Spot potential high-upside names early by checking out these 3543 penny stocks with strong financials that already show stronger financial footing than many of their peers.
• Target future focused themes by zeroing in on these 27 AI penny stocks that connect artificial intelligence with compelling business models.
• Hunt for possible mispriced opportunities by reviewing these 883 undervalued stocks based on cash flows that stand out on discounted cash flow grounds.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com